ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.21
+0.31 (1.51%)
Oct 20, 2025, 12:43 PM EDT - Market open
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 20 analysts that cover ACADIA Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $29.25, which forecasts a 37.94% increase in the stock price over the next year. The lowest target is $17 and the highest is $40.
Price Target: $29.25 (+37.94%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 7 | 8 | 7 | 8 | 8 | 8 |
| Hold | 6 | 7 | 7 | 7 | 7 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 17 | 19 | 18 | 20 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $34 → $33 | Buy | Maintains | $34 → $33 | +55.62% | Sep 29, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +32.04% | Sep 24, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $35 → $39 | Strong Buy | Maintains | $35 → $39 | +83.92% | Sep 11, 2025 |
| UBS | UBS | Strong Buy Maintains $36 → $39 | Strong Buy | Maintains | $36 → $39 | +83.92% | Sep 9, 2025 |
| UBS | UBS | Strong Buy Maintains $32 → $36 | Strong Buy | Maintains | $32 → $36 | +69.77% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
1.09B
from 957.80M
Increased by 14.01%
Revenue Next Year
1.22B
from 1.09B
Increased by 11.81%
EPS This Year
0.57
from 1.36
Decreased by -57.86%
EPS Next Year
0.86
from 0.57
Increased by 50.92%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1B | 1.4B | |||
| Avg | 1.1B | 1.2B | |||
| Low | 1.0B | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.3% | 27.6% | |||
| Avg | 14.0% | 11.8% | |||
| Low | 8.4% | 0.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.07 | 2.03 | |||
| Avg | 0.57 | 0.86 | |||
| Low | 0.36 | 0.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -21.2% | 253.6% | |||
| Avg | -57.9% | 50.9% | |||
| Low | -73.3% | -23.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.